|Description||Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46% (P < 0.05, p < 0.001), respectively.|
Cevimeline hydrochloride is a selective M1 receptor agonist.
GYKI-46903 is a Muscarinic M3 receptor and Serotonin 3 receptor antagonist. In displacement studies, the pIC50 values of GYKI-46903 against [3H]granisetron bind...
Alvameline, also known as Lu25-109, is a partial M1agonist and M2/M3antagonist that was progressed into clinical studies for the treatment of Alzheimer's diseas...
Oxyphencyclimine is a muscarinic cholinergic receptor antagonist and trade name is called as Daricon. Now it is applicated for the treatment of peptic ulcers an...
Tubocurarine hydrochloride pentahydrate
Tubocurarine is a toxic alkaloid. It is an acetylcholine receptor (AChR)-blocking agent. Tubocurarine is now rarely used as an adjunct for clinical anesthesia b...
This active molecular is a muscarinic agonist agent.
Pyrithioxin, a pyridine thiol derivatives, could be used in the treatment of traumatic brain injury sequelae and some sorts of cerebral infarct patients with He...
CDD0102 is a selective M1 agonist which stimulated the secretion of APP from CHO-K1 cells expressing M1 receptors and penetrated into the brain following i.p. a...